CN111436597B - Lipotide and its production process - Google Patents

Lipotide and its production process Download PDF

Info

Publication number
CN111436597B
CN111436597B CN202010252471.7A CN202010252471A CN111436597B CN 111436597 B CN111436597 B CN 111436597B CN 202010252471 A CN202010252471 A CN 202010252471A CN 111436597 B CN111436597 B CN 111436597B
Authority
CN
China
Prior art keywords
mixture
parts
weight
vitamin
beta
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202010252471.7A
Other languages
Chinese (zh)
Other versions
CN111436597A (en
Inventor
方益胜
石汉平
李增宁
余震
丛明华
李涛
刘新旗
倪锐
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shandong Ruoyuote Medical Food Co ltd
Original Assignee
Shandong Ruoyuote Medical Food Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shandong Ruoyuote Medical Food Co ltd filed Critical Shandong Ruoyuote Medical Food Co ltd
Priority to CN202010252471.7A priority Critical patent/CN111436597B/en
Publication of CN111436597A publication Critical patent/CN111436597A/en
Application granted granted Critical
Publication of CN111436597B publication Critical patent/CN111436597B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/175—Amino acids
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/18—Peptides; Protein hydrolysates
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/19—Dairy proteins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
    • A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Polymers & Plastics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pediatric Medicine (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention provides the field of foods and special foods, and in particular relates to a lipopeptide and a production process thereof, wherein the lipopeptide comprises the following nutrients in parts by weight: 45-55 parts of protein, 20-25 parts of fat, 15-25 parts of carbohydrate, 5-10 parts of dietary fiber, 0.3-0.6 part of sodium, 0.01-0.02 part of vitamin E, 0.1-0.3 part of vitamin C and 0.008-0.012 part of zinc; aiming at the problems of insufficient nutritional value, poor effect, insufficient absorption and the like of nutritional products of tumor patients, the invention provides the lipopeptide which is reasonably matched with protein, fat, dietary fiber and the like, and particularly a high-quality protein matrix consisting of whole protein, short peptide and amino acid is prepared, so that the characteristics of quick nutrition absorption, high value and the like are realized, and the supply of the protein and energy requirements of the patients is greatly improved.

Description

Lipotide and its production process
Technical Field
The invention relates to the field of foods and special foods, in particular to a lipopeptide and a production process thereof.
Background
Tumor itself is a wasting disease, and patients commonly have malnutrition, and weight loss is not only the main symptom of tumor patients, but also the cause of worsening prognosis. Patients with non-terminal-stage tumors often cannot perform surgery, radiation or chemotherapy due to worsening of the disease condition caused by malnutrition, but if the patients are well-configured with nutrition, the probability of worsening of the disease condition of the patients can be avoided or reduced to a certain extent by adopting nutrition therapy, so that the effect of improving the disease condition is achieved.
The highest goals of nutritional therapy are metabolic regulation, tumor control, quality of life improvement, and survival prolongation, and the basic requirements are to meet more than 70% of the target energy demand and 100% of the protein demand of tumor patients.
Disclosure of Invention
In order to overcome the problems of insufficient nutritional value, poor effect, insufficient absorption and the like of nutrition for tumor patients in the prior art, the invention provides the lipopeptide which is reasonably matched with protein, fat, dietary fiber and the like, and particularly a high-quality protein matrix consisting of whole protein, short peptide and amino acid is prepared, so that the characteristics of quick nutrition absorption, high value and the like are realized, and the supply of the protein and energy requirements of patients is greatly improved.
The invention is realized by the following technical scheme.
The lipopeptide comprises the following nutrients in parts by weight:
Figure GDA0004152021910000011
preferably, the nutritional ingredients include, in parts by weight:
Figure GDA0004152021910000012
/>
Figure GDA0004152021910000021
preferably, the protein source is one or more of isolated whey protein, short peptides, amino acids, casein, sodium caseinate. The purity of the separated whey protein is 88-95%, and the separated whey protein is processed by the technologies of filtering, drying and the like on the basis of concentrating the whey protein, so that lactose in the separated whey protein is completely removed, and the separated whey protein has the characteristic of quick absorption.
Preferably, the short peptide is one or more of collagen peptide, wheat oligopeptide and sea cucumber peptide.
Preferably, the amino acid is one or more of arginine, glutamine and leucine.
Preferably, the fat source is one or more of medium chain triglyceride microcapsule powder, linseed oil microcapsule powder and fish oil microcapsule.
Preferably, the dietary fiber source is one or more of resistant dextrin, inulin, isomaltooligosaccharide, trehalose, mannose oligomer, microcrystalline cellulose.
Preferably, the raw material sources comprise the following components in parts by weight:
Figure GDA0004152021910000022
/>
Figure GDA0004152021910000031
preferably, the composition further comprises an immunonutrient, wherein the immunonutrient is contained in an amount of 1.2-7 parts by weight.
Preferably, the source of the immunonutrient is one or more of disodium 5 '-inosinate, disodium 5' -guanylate, soybean phospholipid, citric acid, zinc gluconate, and Lentinus edodes extract.
Preferably, the immune nutrient comprises the following components in parts by weight:
Figure GDA0004152021910000032
preferably, the calcium beta-hydroxy-beta-methylbutyrate is also included, and the content of the calcium beta-hydroxy-beta-methylbutyrate is 1-3 parts by weight.
The invention also provides a production process of the lipopeptide, which comprises the following steps:
step one: weighing 0.02-0.07 weight part of sucralose, 0.01-0.05 weight part of disodium 5 '-guanylate, 0.01-0.05 weight part of disodium 5' -inosinate, 0.08-0.2 weight part of zinc gluconate, 0.02-0.06 weight part of vitamin E and 0.15-0.3 weight part of vitamin C, and uniformly mixing to form a first mixture;
step two: weighing 0.4-0.7 part by weight of mannose oligomer, 0.2-0.7 part by weight of lentinus edodes extract, 0.3-1 part by weight of sea cucumber peptide, 0.15-0.4 part by weight of bitter shielding essence and 0.2-0.7 part by weight of milk essence. Mixing the first mixture and the second mixture in a three-dimensional mixer, and sieving with a 40-mesh sieve to form a second mixture;
step three: weighing 0.5-3 parts by weight of citric acid, 0.5-2 parts by weight of microcrystalline cellulose, 0.5-3 parts by weight of soybean lecithin, 0.5-2 parts by weight of isomaltulose, 0.8-5 parts by weight of wheat oligopeptide, 0.8-5 parts by weight of leucine, 1-3 parts by weight of beta-hydroxy-beta-methylbutyrate calcium, 0.8-3 parts by weight of glutamine and 1-10 parts by weight of fish oil microcapsule. And putting the first mixed material and the second mixed material into a three-dimensional mixer for mixing to form a third mixed material;
step four: weighing 1-9 parts by weight of inulin, 5-9 parts by weight of collagen peptide, 8-20 parts by weight of linseed oil microcapsule powder and 2-6 parts by weight of arginine. Mixing the mixture and the third mixture in a three-dimensional mixer, and sieving the mixture with a 40-mesh sieve to form a fourth mixture;
step five: weighing 10-20 parts by weight of medium chain triglyceride microcapsule powder and 20-60 parts by weight of isolated whey protein. And putting the mixture and the fourth mixture into a square cone mixer for mixing to obtain the required lipopeptid.
Preferably, the mixing frequency of the three-dimensional mixer in the second step, the third step and the fourth step is 40Hz, and the mixing time is 30min. And wherein the capacity of the three-dimensional mixer in the second step is 20L, and the capacity of the three-dimensional mixer in the third step and the fourth step is 200L.
Preferably, in the fifth step, the mixing speed of the square cone mixer is 9rpm, the mixing time is 45min, and the capacity is 600L.
Glutamine can enhance intestinal barrier, and can maintain gastrointestinal flora balance and promote nutrient absorption in combination with various dietary fibers (resistant dextrin, inulin, isomaltooligosaccharide, trehalose, mannose oligosaccharide, and microcrystalline cellulose).
The active polysaccharide and the polymer thereof have good pharmacological activity in various aspects of immunoregulation, anti-tumor, anti-inflammatory, anti-radiation, cholesterol reduction, blood pressure reduction, thrombus resistance and the like.
The lentinan can induce the generation of immunocompetent cytokines to play a role in defending and killing tumor cells, and can be used in combination with other treatment means, so that the inhibition of surgery and radiotherapy and chemotherapy on immune functions can be relieved, the chemotherapy tolerance can be increased, the survival rate can be improved, and the quality of life can be improved.
For patients receiving large cervical and abdominal surgeries, enteral nutrition containing immunomodulatory components (arginine, omega-3 fatty acids and nucleotides) may be considered for perioperative use.
The invention has the beneficial effects that:
the lipid chain peptide formula system formed by matching high-quality protein matrix, fat supply matrix, immune regulation factor, active polysaccharide, antioxidant and the like is adopted, the supply of protein and energy is considered, and the purposes of maintaining balanced and sufficient absorption of nutrition in a patient body are achieved in aspects of stimulating mTOR (mammalian target of glucose) channel, cholesterol synthesis, mitochondrial biosynthesis, calcium ion release in SR, satellite cell proliferation, inhibiting ubiquitin-proteasome system, inhibiting autophagy-caspase system and the like.
Detailed Description
The present invention will be described in further detail with reference to examples. It should be understood that the specific embodiments described herein are for purposes of illustration only and are not intended to limit the scope of the invention.
The lipopeptide comprises the following nutrients in parts by weight:
Figure GDA0004152021910000041
as a preferred embodiment, the nutritional ingredients include, in parts by weight:
Figure GDA0004152021910000051
/>
as a preferred embodiment, the protein source is one or more of isolated whey protein, short peptides and amino acids. The purity of the separated whey protein is 88-95%, and the separated whey protein is processed by technologies such as secondary filtration, drying and the like on the basis of concentrating the whey protein, so that lactose in the WPC is completely removed, and the separated whey protein has the characteristic of quick absorption.
As a preferred embodiment, the short peptide is one or more of collagen peptide, wheat oligopeptide and sea cucumber peptide.
As a preferred embodiment, the amino acid is one or more of arginine, glutamine and leucine.
As a preferred embodiment, the fat source is one or more of linseed oil microcapsule powder, fish oil microcapsule, and medium chain triglyceride microcapsule powder.
As a preferred embodiment, the dietary fiber source is one or more of resistant dextrin, inulin, isomaltooligosaccharide, trehalose, mannose oligocarbonate, microcrystalline cellulose.
As a preferred embodiment, the raw material sources comprise the following components in parts by weight:
Figure GDA0004152021910000052
Figure GDA0004152021910000061
as a preferred embodiment, the composition further comprises an immunonutrient, wherein the immunonutrient is contained in an amount of 1.2-7 parts by weight.
As a preferred embodiment, the source of the immunonutrient is one or more of disodium 5 '-inosinate, disodium 5' -guanylate, soybean lecithin, citric acid, zinc gluconate, and shiitake extract.
Preferably, the immune nutrient comprises the following components in parts by weight:
Figure GDA0004152021910000062
as a preferred embodiment, it further comprises calcium beta-hydroxy-beta-methylbutyrate in an amount of 1 to 3 parts by weight.
The invention also provides a production process of the lipopeptide, which comprises the following steps:
step one: weighing 0.02-0.07 weight part of sucralose, 0.01-0.05 weight part of disodium 5 '-guanylate, 0.01-0.05 weight part of disodium 5' -inosinate, 0.08-0.2 weight part of zinc gluconate, 0.02-0.06 weight part of vitamin E and 0.15-0.3 weight part of vitamin C, and uniformly mixing to form a first mixture;
step two: weighing 0.4-0.7 part by weight of mannose oligomer, 0.2-0.7 part by weight of lentinus edodes extract, 0.3-1 part by weight of sea cucumber peptide, 0.15-0.4 part by weight of bitter shielding essence and 0.2-0.7 part by weight of milk essence. Mixing the first mixture and the second mixture in a three-dimensional mixer, and sieving with a 40-mesh sieve to form a second mixture;
step three: weighing 0.5-3 parts by weight of citric acid, 0.5-2 parts by weight of microcrystalline cellulose, 0.5-3 parts by weight of soybean lecithin, 0.5-2 parts by weight of isomaltulose, 0.8-5 parts by weight of wheat oligopeptide, 0.8-5 parts by weight of leucine, 1-3 parts by weight of beta-hydroxy-beta-methylbutyrate calcium, 0.8-3 parts by weight of glutamine and 1-10 parts by weight of fish oil microcapsule. And putting the first mixed material and the second mixed material into a three-dimensional mixer for mixing to form a third mixed material;
step four: weighing 1-9 parts by weight of inulin, 5-9 parts by weight of collagen peptide, 8-20 parts by weight of linseed oil microcapsule powder and 2-6 parts by weight of arginine. Mixing the mixture and the third mixture in a three-dimensional mixer, and sieving the mixture with a 40-mesh sieve to form a fourth mixture;
step five: weighing 10-20 parts by weight of medium chain triglyceride microcapsule powder and 20-60 parts by weight of isolated whey protein. And putting the mixture and the fourth mixture into a square cone mixer for mixing to obtain the required lipopeptid.
As a preferred embodiment, the mixing frequency of the three-dimensional mixer in the second step, the third step and the fourth step is 40Hz, and the mixing time is 30min. And wherein the capacity of the three-dimensional mixer in the second step is 20L, and the capacity of the three-dimensional mixer in the third step and the fourth step is 200L.
As a preferred embodiment, the mixing speed of the square cone mixer in the fifth step is 9rpm, the mixing time is 45min, and the capacity is 600L.
The beneficial effects of this patent are further described by the specific five sets of examples.
Table 1 material formulation of lipopeptides
Figure GDA0004152021910000071
Figure GDA0004152021910000081
The formula of each raw material in the embodiment is shown in table 1, and the production process of the lipopeptid formed by five groups of formulas is specifically as follows:
(1) Preparation of materials
The method comprises the steps of obtaining separated whey protein, linseed oil microcapsule powder, medium-chain triglyceride microcapsule powder, collagen peptide, arginine, inulin, fish oil microcapsule, glutamine, beta-hydroxy-beta-methylbutyrate calcium, leucine, wheat oligopeptide, sea cucumber peptide, lentinus edodes extract, mannose oligomer, isomaltulose, vitamin C, vitamin E, zinc gluconate, disodium 5 '-guanylate, disodium 5' -inosinate, soybean phospholipid, microcrystalline cellulose, citric acid, bitter screening essence, milk essence and sucralose.
(2) Mixing
And weighing and uniformly mixing sucralose, disodium 5 '-guanylate, disodium 5' -inosinate, zinc gluconate, vitamin E and vitamin C according to the formula amount to form a first mixture.
Weighing mannose oligomer, lentinus Edodes extract, sea cucumber peptide, bitter shielding essence and milk essence, mixing with the first mixture in a three-dimensional mixer at 40Hz for 30min, and sieving with 40 mesh sieve to obtain second mixture.
Weighing citric acid, microcrystalline cellulose, soybean lecithin, isomaltulose, wheat oligopeptide, leucine, beta-hydroxy-beta-methylbutyrate calcium, glutamine and fish oil microcapsules according to the formula amount, and placing the microcapsules and the second mixture into a three-dimensional mixer to be mixed for 30min at the frequency of 40Hz to form a third mixture.
Weighing inulin, collagen peptide, linseed oil microcapsule powder and arginine according to the formula amount, putting the inulin, collagen peptide, linseed oil microcapsule powder and arginine and the third mixture into a three-dimensional mixer, mixing for 30min at the frequency of 40Hz, and sieving with a 40-mesh screen to form a fourth mixture.
The medium chain triglyceride microcapsule powder and the separated whey protein with the formula amount are weighed, and are put into a square cone mixer together with the fourth mixture to be mixed for 45min at the rotating speed of 9 rpm.
By adopting a gradient mixing dry process, various materials can be fully and uniformly mixed.
(3) Inner bag
And transferring the mixed materials to an inner package room for packaging.
(4) Outsourcing
And transferring the product finished by the inner package to an outer package room for packaging.
Test example 1
Effect on body weight of H22 tumor-bearing mice
Test group:
test 1 group: cisplatin for injection (20 mg/min, manufactured by zilutu pharmaceutical Co., ltd.).
Test 2 group: cisplatin for injection (20 mg/min, manufactured by zilutu pharmaceutical Co., ltd.) +example II.
The test method comprises the following steps: collecting Kunming mice (male, body weight 18-22 g); extracting ascites of H22 liver cancer mice passaged for 7d in abdominal cavity under aseptic condition, and regulating cell concentration to 1×10 with physiological saline 7 /ml. The H22 tumor cell suspensions were inoculated, 0.2ml each, subcutaneously in the right axilla of kunming mice, according to the anticancer drug study screening protocol. After 7d inoculation of H22 liver cancer cells, selecting tumor body as 100mm 3 The left and right mice were grouped into control group, test 1 group, test 2 group, test 1 group dailyCisplatin is injected into the abdominal cavity at a concentration of 10mg/kg, 1 time a day; the test group 2 was intraperitoneally injected with cisplatin 10mg/kg daily, and the second group of examples was given 4.5g/kg by gavage 1 time daily; the control group is infused with 0.4ml of physiological saline for stomach every day, 1 time every day; after 12d of continuous administration, the mice were weighed and the test results are shown in Table 2.
TABLE 2 influence of Lipopeptides of the invention in combination with cisplatin on H22 tumor-bearing mice weight
Figure GDA0004152021910000091
Note that: p <0.01 compared to control group; compare #p <0.05 to trial 1.
Conclusion of the test: the experiment shows that after cisplatin treatment, the weight of the mice is increased, but the weight of the mice is obviously increased by adding the lipopeptides, which further shows that the lipopeptides have good effect on supplementing nutrition to cancer patients.
Test example 2
Clinical pre-experiment: the lipopeptides obtained in example two are useful for clinical nutrition of malignant tumors.
50 patients with malignant tumor were randomly selected, with ages ranging from 30-60 years, average age of 48.6 years, with 23 females and 27 males. When the medicine is eaten, about 150ml of warm water is measured, the medium is added into the first bag of the lipopeptide in the second embodiment, and the medicine is drunk after being fully and uniformly stirred for 3 months, and the treatment of other medicines is not stopped within 3 months according to the doctor's advice. The related indexes of albumin, C-reactive protein, albumin and interleukin-6 before and after 3 months of patients are tested, wherein the related indexes before and after treatment are shown as follows:
TABLE 3 changes in the indices of malignancy patients before and after treatment
Prealbumin (mg/L) C reactive protein (mg/L) Albumin (g/L) Interleukin-6 (pg/ml)
Before treatment 146±47.31 36±14.86 33±3.24 28±6.81
After treatment 162±64.86 26±20.32 45±4.61 22±4.58
P 0.054 0.028 0.008 0.013
It can be seen from the table that after the lipopeptid is eaten, the nutrition state of a malignant tumor patient is improved relatively, the blood albumin and the albumin can be steadily improved, the physical ability of the patient is improved, the immunity is increased, the effect of resisting inflammatory factors is enhanced, various cytokines are balanced in the body, the disease progress is effectively relieved, and the risk of disease deterioration is reduced.
While the foregoing description illustrates and describes the preferred embodiments of the present invention, as noted above, it is to be understood that the invention is not limited to the forms disclosed herein but is not to be construed as excluding other embodiments, and that various other combinations, modifications and environments are possible and may be made within the scope of the inventive concepts described herein, either by way of the foregoing teachings or by those of skill or knowledge of the relevant art. And that modifications and variations which do not depart from the spirit and scope of the invention are intended to be within the scope of the appended claims.

Claims (1)

1. The lipopeptides are characterized by comprising the following nutrients in parts by weight:
isolated whey protein 40, linseed oil microcapsule powder 10, medium chain triglyceride microcapsule powder 20, collagen peptide 9, arginine 2, inulin 2, fish oil microcapsule 1, glutamine 0.8, beta-hydroxy-beta-methylbutyrate calcium 1, leucine 0.8, wheat oligopeptide 0.8, soybean lecithin 3, citric acid 2.4, microcrystalline cellulose 0.5, isomaltulose 0.5, lentinus edodes extract 0.2, sea cucumber peptide 0.3, mannose oligomer 0.7, vitamin C0.3, vitamin E0.06, zinc gluconate 0.2,5 '-disodium inosinate 0.01,5' -guanylate 0.05, bitter taste masking essence 0.4, milk essence 0.7 and sucralose 0.07;
the preparation method of the lipopeptid comprises the following steps:
(1) Preparation of materials
Collecting separated whey protein, linseed oil microcapsule powder, medium-chain triglyceride microcapsule powder, collagen peptide, arginine, inulin, fish oil microcapsule, glutamine, beta-hydroxy-beta-methylbutyrate calcium, leucine, wheat oligopeptide, sea cucumber peptide, lentinus edodes extract, oligomeric mannose, isomaltulose, vitamin C, vitamin E, zinc gluconate, 5 '-guanylate disodium, 5' -inosinic acid disodium, soybean phospholipid, microcrystalline cellulose, citric acid, bitter screening essence, milk essence and sucralose;
(2) Mixing
Weighing sucralose, disodium 5 '-guanylate, disodium 5' -inosinate, zinc gluconate, vitamin E and vitamin C according to the formula amount, and uniformly mixing to form a first mixture;
weighing mannose oligomer, lentinus Edodes extract, sea cucumber peptide, bitter shielding essence and milk essence, mixing with the first mixture in a three-dimensional mixer at 40Hz for 30min, and sieving with 40 mesh sieve to obtain second mixture;
weighing citric acid, microcrystalline cellulose, soybean lecithin, isomaltulose, wheat oligopeptide, leucine, beta-hydroxy-beta-methylbutyrate calcium, glutamine and fish oil microcapsules with the formula amount, and putting the microcapsules and the second mixture into a three-dimensional mixer to be mixed for 30min at the frequency of 40Hz to form a third mixture;
weighing inulin, collagen peptide, linseed oil microcapsule powder and arginine according to the formula amount, putting the inulin, collagen peptide, linseed oil microcapsule powder and arginine and the third mixture into a three-dimensional mixer, mixing for 30min at the frequency of 40Hz, and sieving with a 40-mesh screen to form a fourth mixture;
weighing medium chain triglyceride microcapsule powder with a formula amount, separating whey protein, and putting the medium chain triglyceride microcapsule powder and the fourth mixture into a square cone mixer to be mixed for 45min at a rotating speed of 9 rpm;
the gradient mixing dry process is adopted, so that various materials can be fully and uniformly mixed;
(3) Inner bag
Transferring the mixed materials to an inner packing room for packing;
(4) Outsourcing
And transferring the product finished by the inner package to an outer package room for packaging.
CN202010252471.7A 2020-04-01 2020-04-01 Lipotide and its production process Active CN111436597B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202010252471.7A CN111436597B (en) 2020-04-01 2020-04-01 Lipotide and its production process

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202010252471.7A CN111436597B (en) 2020-04-01 2020-04-01 Lipotide and its production process

Publications (2)

Publication Number Publication Date
CN111436597A CN111436597A (en) 2020-07-24
CN111436597B true CN111436597B (en) 2023-05-12

Family

ID=71649564

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202010252471.7A Active CN111436597B (en) 2020-04-01 2020-04-01 Lipotide and its production process

Country Status (1)

Country Link
CN (1) CN111436597B (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113841889A (en) * 2021-08-10 2021-12-28 许昌学院 Cell absorption combined functional nutrient
CN116036247B (en) * 2023-02-03 2024-04-05 江中药业股份有限公司 Composition for inhibiting inflammatory response, promoting angiogenesis and wound healing and application thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109846029A (en) * 2018-11-23 2019-06-07 广州欧普康特医食品有限公司 A kind of Elental for cancer patient
CN110839884A (en) * 2019-12-04 2020-02-28 上海张新生物医药科技有限公司 Nutritional composition for improving body inflammatory signs of tumor patients and preparation method thereof
CN110892985A (en) * 2019-11-28 2020-03-20 北京诺康达医药科技股份有限公司 Nutritional preparation suitable for perioperative patients

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109846029A (en) * 2018-11-23 2019-06-07 广州欧普康特医食品有限公司 A kind of Elental for cancer patient
CN110892985A (en) * 2019-11-28 2020-03-20 北京诺康达医药科技股份有限公司 Nutritional preparation suitable for perioperative patients
CN110839884A (en) * 2019-12-04 2020-02-28 上海张新生物医药科技有限公司 Nutritional composition for improving body inflammatory signs of tumor patients and preparation method thereof

Also Published As

Publication number Publication date
CN111436597A (en) 2020-07-24

Similar Documents

Publication Publication Date Title
CN106616615A (en) Clinical nutrient formula special for tumor and preparation method of clinical nutrient formula
Namba Maitake D-fraction: healing and preventive potential for cancer
CN107549612B (en) Nutritional formula rice flour capable of improving immunity of 6-12 month-old infants
CN111436597B (en) Lipotide and its production process
CN104432012A (en) Dendrobium compound superfine powder and preparation method thereof
CN112089051A (en) Nutritional composition for improving body inflammatory signs of tumor patients and preparation method thereof
CN113575934A (en) Total-nutrient compound protein powder for tumor patients
CN104738638A (en) Composition with anti-fatigue effect and application thereof
CN109602021A (en) Nutraceutical containing sialic acid
CN111493326A (en) Enteral nutrition food and preparation method and application thereof
CN107981339A (en) Tumour full nutrition formula food
CN106376934A (en) Ketogenic-diet composition containing active polysaccharide, and preparation and application methods thereof
CN111480839A (en) Special clinical nutrition formula for bone cancer and preparation method thereof
CN110150654A (en) A kind of special medicine purposes formula food for tumor patient
CN111802633A (en) Special clinical nutrition formula for esophageal cancer and preparation method thereof
CN108783465A (en) A kind of nutrition formula product with oncotherapy function
CN111449247A (en) Tumor patient sea cucumber peptide nutritional supplement and processing method thereof
CN114868890A (en) Multi-vitamin nutrient formula suitable for tumor patients
CN113244246B (en) Application of microbial plasmalogen in treatment of colon cancer
CN101167760B (en) Mushroom fermentation oral liquid with anti-tumor activity and preparation method
CN101574145A (en) Nutritional reinforced supplement
CN115053929A (en) Formula milk powder suitable for people with fatty liver and preparation method thereof
CN112544712A (en) Lentinan soluble bean for improving intestinal immunity of children by diet and preparation method thereof
CN110419721A (en) A kind of tumour tailored version clinic special dietary formula and preparation method thereof
JP2017171595A (en) Bdnf production promoting agent

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant